title: [The course of hepatitis C infection after liver transplantation].
abstract: HCV infection is an important health problem all over the world. Hepatitis C is the main reason for liver cirrhosis and liver failure which is one of most common indication for liver transplantation (OLT). HCV-associated liver cirrhosis appears at 20-25% of infected patients within 20 years. Recurrence of HVC infection nearly universally follows transplantation and may lead to graft loss. Acute hepatitis appeared in 75% of patients. The rate of HCV cirrhosis on the graft is variable from 8 to 25% at 5 years. Antiviral treatment with combination therapy interferon-ribavirin gave promising results. Attempts to introduce prophylactic post-transplant antiviral treatment are still under evaluation. This paper presents clinical and therapeutical issues of recurrent hepatitis C after liver transplantation.
authors.affiliation: Klinika Immunologii, Transplantologii i Chorób Wewngtrznych, Akademii Medycznej, Warszawie. leszekpaczek@onet.pl
authors.forename: Urszula
authors.initials: U
authors.lastname: Ołdakowska-Jedynak
authors.forename: Leszek
authors.initials: L
authors.lastname: Paczek
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D006526:Hepatitis C / Q000503:physiopathology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000821:virology*; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons